[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604111":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":26,"responsibleParty":31,"collaborators":26,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":41,"eligibilityCriteria":42,"healthyVolunteers":37,"sex":43,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":26,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":26,"overallStatus":56,"whyStopped":26,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":26},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"(control group)","PLACEBO_COMPARATOR","22 patients will continue their standard antiviral therapy (Entecavir 0.5 mg) for 6 months.",[13],"Drug: Entecavir (ETV)",{"label":15,"type":16,"description":17,"interventionNames":18},"(zinc group)","ACTIVE_COMPARATOR","22 patients will receive Zinc suIphate 220 mg orally once daily (equivalent to 50 mg elemental zinc), in addition to their standard antiviral therapy (Entecavir 0.5 mg), for 6 months.",[19],"Drug: Zinc (zinc sulphate)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Entecavir (ETV)","Standard antiviral therapy with Entecavir 0.5 mg orally once daily for 6 months.\"(control group)",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Zinc (zinc sulphate)","Zinc sulfate 220 mg orally once daily (50 mg elemental zinc) in addition to Entecavir 0.5 mg, for 6 months.\"",[15],{"type":32,"investigatorFullName":33,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Dina Ahmed Mohamed Ragai Elrefaey","clinical pharmacist","100604111","phase-2-zinc-sulphate-in-treatment-fibrosis-in-hbv-patient-receiving-antiviral-therapy-100604111",false,"NCT07145268","Zinc Sulphate in Treatment Fibrosis in HBV Patient Receiving Antiviral Therapy","Clinical Study to Evaluate the Possible Antifibrotic Effect of Zinc Sulphate in Chronic HBV Patient Receiving Anti Viral Therapy","HBV","Inclusion Criteria:\n\n* Patients with fibrosis stage (F2\\&F3) post chronic HBV infection receiving standard antiviral therapy.\n* Age \\> 18 and \\\u003C 65 years.\n\nExclusion Criteria:\n\n* Patients with prior history of liver transplantation.\n* Patients with prior history of hepatocellular carcinoma.\n* Patients coinfected with HIV or HCV.\n* Patients with any malignancies.\n* Pregnant and lactating women.","ALL","18 Years","65 Years",{"count":47,"type":48},44,"ESTIMATED","INTERVENTIONAL",[51],"PHASE2","This study aims to investigate the possible safety and efficacy of Zinc sulphate as antifibrotic agent in chronic HBV patient receiving antiviral therapy.",[54,55],"Liver Fibroses","HBV (Hepatitis B Virus)","NOT_YET_RECRUITING","2025-08-20",{"date":59,"type":60},"2025-08-28","ACTUAL",{"date":62,"type":48},"2025-09-01",{"date":64,"type":48},"2026-09",{"name":5,"class":6}]